What question did this study set out to answer?

This trial aimed to determine if elevated cardiopulmonary bypass flow could reduce renal injury during cardiac surgery.

Elevated Cardiopulmonary Bypass Flow for Renal Protection in Cardiac Surgery: A Randomized Trial

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial examines elevated bypass flow's effects on renal injury in cardiac surgery, suggesting potential benefits for patients.

This trial aimed to determine if elevated cardiopulmonary bypass flow could reduce renal injury during cardiac surgery.
Single-center, randomized controlled trial with 89 adults undergoing elective cardiac surgery.
Participants were assigned to high-flow (2.9 L·min·m−2) or standard-flow (2.4 L·min·m−2) during CPB.
Primary outcomes included urine biomarkers of renal injury and serum creatinine levels post-CPB.
High-flow significantly reduced renal injury biomarkers: NAG geometric mean ratio 0.43 (95% CI, 0.26 to 0.70, P < .001) and TIMP-2 × IGFBP-7 ratio 0.46 (95% CI, 0.30 to 0.73, P < .001).
Median serum creatinine levels were below baseline in the high-flow group for three days but above baseline in the standard-flow group.
AKI incidence was lower in the high-flow group at 16% vs. 25% in the standard-flow group, odds ratio 1.90 (95% CI, 0.64 to 5.60, P = .248).

Wijk et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark